Exited position

Christopher Bloomstran’s Sanofi Sa (SNY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Semper Augustus Investments Group LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2008Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares123.47KHighest verified quarter-end share count
Quarters reported40Verified quarters with shares above zero
What happened?

Semper Augustus Investments Group LLC first reported Sanofi Sa in Q3 2008. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Semper Augustus Investments Group LLC sold the entire position in Q4 2018, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2018
Sold the entire position−123.47K shares · No shares reported at quarter-end
Q2 2018
Bought 18.6% more+19.39K shares · 123.47K shares reported after the change
Filing context

Quarter-end price $40.01 · Estimated holding basis $37.28

Q1 2018
Sold 1.0% of the position−1.05K shares · 104.09K shares remained
Filing context

Quarter-end price $40.08 · Estimated holding basis $36.77

Q4 2017
Sold 0.05% of the position−50 shares · 105.14K shares remained
Filing context

Quarter-end price $43.00 · Estimated holding basis $36.77

Q2 2017
Sold 0.07% of the position−72 shares · 105.19K shares remained
Filing context

Quarter-end price $47.91 · Estimated holding basis $36.77

Q1 2017
Sold 0.3% of the position−350 shares · 105.26K shares remained
Filing context

Quarter-end price $45.25 · Estimated holding basis $36.77

13 unchanged quarters are collapsed by default.

Portfolio importance

How important was Sanofi Sa in Semper Augustus Investments Group LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight3.2%Q3 2018
Last reported rank#9of 29 reported positions
Peak portfolio weight3.9%Q3 2017
Best historical rank#6Q2 2017
At peak importanceQ3 2017
SNY
3.9%
Largest holding
24.7%
Cross-investor discovery

Who else owns Sanofi Sa?

Also reported by 1 other tracked investor in their latest verified filings.

Ray DalioBridgewater Associates, LP
SNY0.0% of reported portfolio
Explore Sanofi Sa across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$42.592026-09-16

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Semper Augustus Investments Group LLC’s Form 13F disclosures, not Christopher Bloomstran’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.